Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

Leukemia, Published online: 24 February 2020; doi:10.1038/s41375-020-0764-6Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

Source: Leukemia - February 23, 2020 Category: Hematology Authors: Christopher A. Eide Stephen E. Kurtz Andy Kaempf Nicola Long Anupriya Agarwal Cristina E. Tognon Motomi Mori Brian J. Druker Bill H. Chang Alexey V. Danilov Jeffrey W. Tyner Source Type: research